ZEALAND PHARMA A/S DK 1/ DK0060257814 /
05/09/2024 07:57:00 | Chg. -3.2000 | Volume | Bid08:38:20 | Ask08:38:20 | High | Low |
---|---|---|---|---|---|---|
113.5000EUR | -2.74% | - Turnover: - |
112.1000Bid Size: 34 | 113.0000Ask Size: 34 | 113.5000 | 113.5000 |
GlobeNewswire
22/08
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire
12/08
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...
GlobeNewswire
26/06
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...
GlobeNewswire
25/06
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire
25/06
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire
20/06
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire
07/06
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire
07/06
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire
06/06
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire
31/05
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
29/05
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire
23/05
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire
09/05
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
26/02
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
26/02
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...